Axonics® reports fourth quarter and fiscal year 2020 results

Irvine, calif.--(business wire)--axonics modulation technologies, inc. (nasdaq: axnx), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (snm) devices for the treatment of urinary and bowel dysfunction, today reported results for the fourth quarter and fiscal year ended december 31, 2020. raymond w. cohen, axonics ceo, said, “in the first year of axonics' commercial launch in the united states, we exceeded our ambitious goals despite
AXNX Ratings Summary
AXNX Quant Ranking